Shattuck Labs, Inc. Accumulated Other Comprehensive Income
Shattuck Labs, Inc. (STTK) had Accumulated Other Comprehensive Income of -$63.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$63.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $3.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$63.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $6.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $52.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$5.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$14.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $4.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $7.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$74.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$339.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$877.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$1.33M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$1.11M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$527.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$560.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | -$1.83M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$1.62M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$660.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$63.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | -$10.00K 10-Q · filed 2020-11-13 |
| 2019-12-31 | $54.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |